Harmony Biosciences Holdings, Inc.
HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmonyā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$31.43
Price+1.58%
$0.49
1Y
Price
Market Cap
$1.808b
Small
Price/Earnings 3y Avg5y Avg
9.9x
Premium
Premium
Financials Overview
Key metrics over the past few years+29.5%
EBITDA Margin+19.8%
Net Profit Margin+39.6%
Free Cash Flow MarginRevenue
$772.527m
+8.1%
1y CAGR+21.3%
3y CAGR+26.8%
5y CAGREarnings
$180.904m
+24.3%
1y CAGR+2.8%
3y CAGR+108.2%
5y CAGREPS
$3.10
+23.5%
1y CAGR+4.4%
3y CAGR+106.3%
5y CAGRBook Value
$773.080m
$1.108b
Assets$334.928m
Liabilities$172.095m
DebtDebt to Assets
15.5%
0.6x
Debt to EBITDAFree Cash Flow
$258.729m
+18.3%
1y CAGR+42.7%
3y CAGR+1554.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company